Nonresolving inflammation in gp91phox-/- mice, a model of human chronic granulomatous disease, has lower adenosine and cyclic adenosine 5′-monophosphate

Journal of Immunology

Volumn 182, Issue 5, 2009, Pages 3262-3269

  Rajakariar, Ravindra ^a   Newson, Justine ^b   Jackson, Edwin K ^c   Sawmynaden, Precilla ^b   Smith, Andrew ^b   Rahman, Farooq ^b   Yaqoob, Muhammad M ^a   Gilroy, Derek W ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE KINASE; CYCLIC AMP; NONSTEROID ANTIINFLAMMATORY AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; AUTACOID; CYBB PROTEIN, MOUSE; MEMBRANE PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; DISEASE COURSE; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ACUTE DISEASE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOLOGY; LEUKOPENIA; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ACUTE DISEASE; ADENOSINE; ANIMALS; CELLS, CULTURED; CYCLIC AMP; DISEASE MODELS, ANIMAL; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOPENIA; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; NADPH OXIDASE; PERITONITIS;

EID: 64849101844     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0801739     Document Type: Article

References (43)

1. Giroud, J. P., and D. A. Willoughby. 1970. The interrelations of complement and a prostaglandin-like substance in acute inflammation. J. Pathol. 101: 241-249.
2. Spector, W. G., and D. A. Willoughby. 1964. Vasoactive amines in acute inflammation. Ann. NY Acad. Sci. 116: 839-846.
3. Spector, W. G., and D. A. Willoughby. 1964. The effect of vascular permeability factors on the emigration of leukocytes. J. Pathol. Bacteriol. 87: 341-346.
4. Spector, W. G., and D. A. Willoughby. 1962. Salicylate and increased vascular permeability. Nature 196: 1104.
5. Spector, W. G., and D. A. Willoughby. 1957. 5-Hydroxytryptamine in acute inflammation. Nature 179: 318.
6. Choy, E. H., and G. S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344: 907-916.
7. Willoughby, D. A., and W. G. Spector. 1964. Adrenaline precursors in the inflammatory reaction. J. Pathol. Bacteriol. 88: 159-166.
8. Malbica, J. O., and L. G. Hart. 1971. Effect of adenosine triphosphate and some anti-inflammatory agents on a purified lysosomal fraction having high acid phosphatase and labile-glucuronidase activity. Biochem. Pharmacol. 20: 2017-2026.
9. Cronstein, B. N. 1994. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76: 5-13.
10. Sitkovsky, M., and D. Lukashev. 2005. Regulation of immune cells by localtissue oxygen tension: HIF1α and adenosine receptors. Nat. Rev. Immunol. 5: 712-721.
11. Flower, R. J. 1986. The mediators of steroid action. Nature 320: 20.
12. Sutherland, E. W., and T. W. Rall. 1958. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 232: 1077-1091.
13. Conti, P., D. Kempuraj, K. Kandere, M. Di Gioacchino, R. C. Barbacane, M. L. Castellani, M. Felaco, W. Boucher, R. Letourneau, and T. C. Theoharides. 2003. IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol. Lett. 86: 123-129.
14. Levy, B. D., C. B. Clish, B. Schmidt, K. Gronert, and C. N. Serhan. 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2: 612-619.
15. Hurst, S. M., T. S. Wilkinson, R. M. McLoughlin, S. Jones, S. Horiuchi, N. Yamamoto, S. Rose-John, G. M. Fuller, N. Topley, and S. A. Jones. 2001. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705-714.
16. Jamieson, T., D. N. Cook, R. J. Nibbs, A. Rot, C. Nixon, P. McLean, A. Alcami, S. A. Lira, M. Wiekowski, and G. J. Graham. 2005. The chemokine receptor D6 limits the inflammatory response in vivo. Nat. Immunol. 6: 403-411.
17. Ariel, A., G. Fredman, Y. P. Sun, A. Kantarci, T. E. Van Dyke, A. D. Luster, and C. N. Serhan. 2006. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat. Immunol. 7: 1209-1216.
18. 2. Proc. Natl. Acad. Sci. USA 104: 20979-20984.
19. Schwab, J. M., N. Chiang, M. Arita, and C. N. Serhan. 2007. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
20. Rajakariar, R., T. Lawrence, J. Bystrom, M. Hilliard, P. Colville-Nash, G. Bellingan, D. Fitzgerald, M. M. Yaqoob, and D. W. Gilroy. 2008. Novel biphasic role for lymphocytes revealed during resolving inflammation. Blood 111: 4184-4192.
21. Flower, R. J., and J. R. Vane. 1972. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 240: 410-411.
22. Gilroy, D. W., P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5: 698-701.
23. Gilroy, D. W., T. Lawrence, M. Perretti, and A. G. Rossi. 2004. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3: 401-416.
24. Segal, A. W. 1996. The NADPH oxidase and chronic granulomatous disease. Mol. Med. Today 2: 129-135.
25. Pollock, J. D., D. A. Williams, M. A. Gifford, L. L. Li, X. Du, J. Fisherman, S. H. Orkin, C. M. Doerschuk, and M. C. Dinauer. 1995. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat. Genet. 9: 202-209.
26. phox caused granulomatous synovitis and increased connective tissue destruction in experimental arthritis models. Am. J. Pathol. 163: 1525-1537.
27. Morgenstern, D. E., M. A. Gifford, L. L. Li, C. M. Doerschuk, and M. C. Dinauer. 1997. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J. Exp. Med. 185: 207-218.
28. Fredholm, B. B., I. J. AP, K. A. Jacobson, K. N. Klotz, and J. Linden. 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53: 527-552.
29. Hasko, G., and B. N. Cronstein. 2004. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25: 33-39.
30. Jackson, E. K., Z. Mi, M. T. Koehler, J. A. Carcillo, Jr., and W. A. Herzer. 1996. Injured erythrocytes release adenosine deaminase into the circulation. J. Pharmacol. Exp. Ther. 279: 1250-1260.
31. Brown, J. R., D. Goldblatt, J. Buddle, L. Morton, and A. J. Thrasher. 2003. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J. Leukocyte Biol. 73: 591-599.
32. Serhan, C. N., and J. Savill. 2005. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6: 1191-1197.
33. Lawrence, T., D. A. Willoughby, and D. W. Gilroy. 2002. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2: 787-795.
34. Trivedi, S. G., J. Newson, R. Rajakariar, T. S. Jacques, R. Hannon, Y. Kanaoka, N. Eguchi, P. Colville-Nash, and D. W. Gilroy. 2006. Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc. Natl. Acad. Sci. USA 103: 5179-5184.
35. Serhan, C. N. 2002. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat. 68-. 69: 433-455.
36. Matsuoka, T., and S. Narumiya. 2007. Prostaglandin receptor signaling in disease. Sci. World J. 7: 1329-1347.
37. Ohta, A., and M. Sitkovsky. 2001. Role of G-protein-coupled adenosine receptors in down-regulation of inflammation and protection from tissue damage. Nature 414: 916-920.
38. Gokal, R. 1993. Quality of life in patients undergoing renal replacement therapy. Kidney Int. Suppl. 40: S23-S27.
39. Fredholm, B. B., K. Battig, J. Holmen, A. Nehlig, and E. E. Zvartau. 1999. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51: 83-133.
40. Martin, M. C., I. Dransfield, C. Haslett, and A. G. Rossi. 2001. Cyclic AMP regulation of neutrophil apoptosis occurs via a novel protein kinase A-independent signaling pathway. J. Biol. Chem. 276: 45041-45050.
41. Rossi, A. G., J. C. McCutcheon, N. Roy, E. R. Chilvers, C. Haslett, and I. Dransfield. 1998. Regulation of macrophage phagocytosis of apoptotic cells by cAMP. J. Immunol. 160: 3562-3568.
42. Goldblatt, D. 2002. Current treatment options for chronic granulomatous disease. Exp. Opin. Pharmacother. 3: 857-863.
43. Ohta, A., D. Lukashev, E. K. Jackson, B. B. Fredholm, and M. Sitkovsky. 2007. 1,3,7-Trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism. J. Immunol. 179: 7431-7438.